YTS-104

N/A

Report date: 2024/01/24 13:32:27

Base Information

Drug NameYTS-104
Drug Alias NameLILRB4 STAR-T合成性T细胞受体抗原受体(STAR-T)疗法（华夏英泰）LILRB4 STAR-T CellsLILRB4 STAR-T CellLILRB4 STAR-T +[6] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Leukocyte immunoglobulin-like receptor subfamily B member 4Antibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocyte replacements
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 4
Therapy Area/IndicationsLeukemia, Myeloid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChina Immunotech Co LtdBeijing Qingyi Taike Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChina Immunotech Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A